Halozyme Therapeutics Inc
NASDAQ:HALO

Watchlist Manager
Halozyme Therapeutics Inc Logo
Halozyme Therapeutics Inc
NASDAQ:HALO
Watchlist
Price: 71.47 USD -1.31%
Market Cap: 8.4B USD
Section:
 

Relative Value

The Relative Value of one HALO stock under the Base Case scenario is 94.83 USD. Compared to the current market price of 71.47 USD, Halozyme Therapeutics Inc is Undervalued by 25%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

HALO Relative Value
Base Case
94.83 USD
Undervaluation 25%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

6.8
P/S
P/S
Price to Sales
6.8
vs History
65
vs Industry
49
Median 3Y
6.7
Median 5Y
7.6
Industry
8.2
Forward
6.1
More Details
14.2
P/E
P/E
Price to Earnings
14.2
vs History
74
vs Industry
8
Median 3Y
17.4
Median 5Y
17.7
Industry
24.2
Forward
11.1
More Details
13.9
P/OCF
P/OCF
Price to OCF
13.9
vs History
73
vs Industry
11
Median 3Y
14.7
Median 5Y
16.6
Industry
23
More Details
14.1
P/FCFE
P/FCFE
Price to FCFE
14.1
vs History
34
vs Industry
9
Median 3Y
13.3
Median 5Y
12.8
Industry
25.5
More Details
16.8
P/B
P/B
Price to Book Value
16.8
vs History
80
vs Industry
3
Median 3Y
22.7
Median 5Y
24.9
Industry
3.3
More Details
6.8
EV/S
EV/S
Enterprise Value to Sales
6.8
vs History
87
vs Industry
39
Median 3Y
7.7
Median 5Y
8.8
Industry
8.6
Forward
6.2
More Details
8.1
EV/GP
EV/GP
Enterprise Value to Gross Profit
8.1
vs History
88
vs Industry
38
Median 3Y
9.6
Median 5Y
11.3
Industry
10.5
More Details
10.4
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
10.4
vs History
90
vs Industry
10
Median 3Y
14.1
Median 5Y
17.6
Industry
6.1
Forward
9.5
More Details
11.5
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
11.5
vs History
90
vs Industry
9
Median 3Y
17
Median 5Y
19.5
Industry
6.6
Forward
10.2
More Details
13.9
EV/OCF
EV/OCF
Enterprise Value to OCF
13.9
vs History
88
vs Industry
9
Median 3Y
16.6
Median 5Y
19.1
Industry
8.8
More Details
14.1
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
14.1
vs History
88
vs Industry
7
Median 3Y
17.1
Median 5Y
19.4
Industry
6.8
More Details
5.6
EV/IC
EV/IC
Enterprise Value to IC
5.6
vs History
38
vs Industry
27
Median 3Y
5.2
Median 5Y
5.6
Industry
5.7
More Details

Multiples Across Competitors

HALO Competitors Multiples
Halozyme Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Halozyme Therapeutics Inc
NASDAQ:HALO
8.4B USD 6.8 14.2 10.4 11.5
IL
Can Fite Biopharma Ltd
TASE:CANF
157.8T ILS 57 538 940.5 -3 951 404.2 -3 877 537.1 -3 868 905.8
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 004 331.7 -161 617.5 -196 255.2 -194 015.7
US
Abbvie Inc
NYSE:ABBV
382.8B USD 6.4 163.2 15.9 22.5
US
Amgen Inc
NASDAQ:AMGN
172.7B USD 4.8 24.7 17.9 17.9
US
Gilead Sciences Inc
NASDAQ:GILD
150B USD 5.1 18.4 12.4 12.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
116.5B USD 9.9 31.7 23.3 24.3
US
Epizyme Inc
F:EPE
94.1B EUR 2 071.8 -528.7 -575.7 -560.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.6B USD 5.5 17.3 16.6 18.8
AU
CSL Ltd
ASX:CSL
83.9B AUD 3.6 18.8 12.7 15.8
NL
argenx SE
XBRU:ARGX
42.2B EUR 13.7 32.2 55.2 56.7
P/S Multiple
Revenue Growth P/S to Growth
US
Halozyme Therapeutics Inc
NASDAQ:HALO
Average P/S: 8 322 309.1
6.8
24%
0.3
IL
C
Can Fite Biopharma Ltd
TASE:CANF
57 538 940.5
140%
410 992.4
FR
Pharnext SCA
OTC:PNEXF
34 004 331.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.4
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.8
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.1
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.9
10%
1
US
E
Epizyme Inc
F:EPE
2 071.8
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.5
6%
0.9
AU
CSL Ltd
ASX:CSL
3.6
5%
0.7
NL
argenx SE
XBRU:ARGX
13.7
49%
0.3
P/E Multiple
Earnings Growth PEG
US
Halozyme Therapeutics Inc
NASDAQ:HALO
Average P/E: 40.1
14.2
37%
0.4
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -3 951 404.2 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 617.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
163.2
89%
1.8
US
Amgen Inc
NASDAQ:AMGN
24.7
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
18.4
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.7
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -528.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.3
10%
1.7
AU
CSL Ltd
ASX:CSL
18.8
11%
1.7
NL
argenx SE
XBRU:ARGX
32.2
40%
0.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Halozyme Therapeutics Inc
NASDAQ:HALO
Average EV/EBITDA: 20.5
10.4
32%
0.3
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -3 877 537.1 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 255.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.9
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
17.9
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.4
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.3
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -575.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.6
11%
1.5
AU
CSL Ltd
ASX:CSL
12.7
8%
1.6
NL
argenx SE
XBRU:ARGX
55.2
810%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Halozyme Therapeutics Inc
NASDAQ:HALO
Average EV/EBIT: 22.5
11.5
34%
0.3
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -3 868 905.8 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 015.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.5
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
17.9
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.4
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.3
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -560.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.8
13%
1.4
AU
CSL Ltd
ASX:CSL
15.8
11%
1.4
NL
argenx SE
XBRU:ARGX
56.7
N/A N/A

See Also

Summary
HALO intrinsic value, competitors valuation, and company profile.
DCF Valuation
HALO stock valuation using Discount Cash Flow valuation method.
Relative Valuation
HALO stock valuation using valuation multiples.
Wall Street Estimates
HALO price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
HALO stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 309,300+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.